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CObjectives: To assess value for money of providing systematic screen-
ing for osteoporosis among postmenopausal women and medical
treatments for those diagnosed with osteoporosis as evidence-based
decision making for the revision of the National List of Essential
Medicines. Methods: Decision analytic models were constructed, us-
ing a societal perspective, to assess the cost per quality-adjusted life-
years (QALYs) gained from systematic screening using the Osteoporo-
sis Self-Assessment Tool and dual-energy X-ray absorptiometry or
dual-energy X-ray absorptiometry alone compared with no screening.
Alendronate, risedronate, raloxifene, and nasal calcitonin were eco-
nomically evaluated to determine a treatment of choice for the preven-
tion of osteoporosis-related fractures. Most input parameters were
obtained from literature reviews, and systematic reviews and meta-
analyses, if available. The service costs and related household ex-
penses were based on the Thai setting. Probabilistic and one-way sen-
sitivity analyses were used to incorporate the impact of parameter O
e no
entio
onth
al So
doi:10.1016/j.jval.2011.11.015ncertainty. Results: The Osteoporosis Self-Assessment Tool and se-
uential dual-energy X-ray absorptiometry provided better value for
oney for osteoporosis screening among young age groups (60 years
ld). Although there was no significant difference in cost per QALY for
lder age groups, alendronate provided the lowest incremental cost-
ffectiveness ratio while nasal calcitonin presented the highest incre-
ental cost-effectiveness ratio. It was shown that providing medica-
ion for a secondary prevention yielded a much higher cost per QALY
ained compared with providing medication for a primary prevention.
onclusions: Given the benchmark set at 100,000 Thai baht per QALY
ained, providing systematic screening and treatment for osteoporosis
as cost-ineffective in the Thai setting.
eywords: cost-utility analysis, decision analysis model, postmeno-
ausal osteoporosis, screening, treatment.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background
Osteoporosis is one of the most significant factors contributing to
fractures in postmenopausal womenworldwide. It is caused by an
imbalance between bone formation and bone resorption, often
defined by a reduction in bone mineral density (BMD). BMD
reaches its maximum at the age of 20 to 30 years, and then de-
clines over time [1,2]. It has been estimated that one-fifth of
women aged between 40 and 80 years in Thailand live with osteo-
porosis, resulting in approximately 126,000 hip fractures annually
[3,4]. The mortality rate among those with major fractures is high.
This, in turn, leads to a significant economic burden on society as
well as a reduction in quality of life for those individuals who
survive [1,5–7].
At present, dual-energy X-ray absorptiometry (DXA) is a gold
standard for measuring BMD and is used for the diagnosis and
monitoring of osteoporosis [8]. DXA, however, is relatively expen-
sive, and there is also a lack of information concerning whom to
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Published by Elsevier Inc.examine, the potential risks and benefits of undertaking the test,
and ultimately, whether it is worth offering this service under the
public health insurance scheme. As a result, DXA has rarely been
used by Thai women. The Osteoporosis Self-Assessment Tool
(OST), a risk assessment instrument, was first developed and val-
idated in Asian postmenopausal women [9]. It is a simple tool that
requires only age andweight parameters; however, it is not appro-
priate to be used as a stand-alone method for the diagnosis of
osteoporosis because it has a high sensitivity but low specificity. A
previous study conducted in Thailand showed that screeningwith
OST and sequential DXA for those identified at high risk for osteo-
porosis from OST is the most cost-effective option compared with
other screening modalities [10]. Therefore, OST in conjunction
with DXA is considered to have the potential to be used for osteo-
porosis screening at the national level.
Various medications are currently available in the market to
reduce the risk of fractures among osteoporosis patients. In
Thailand, alendronate has been reported to be the most pre-
scribed drug (39%), followed by raloxifene (26%), nasal calci-
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been no economic evaluation studies conducted in developing
settings. These drugs are not included in the National List of
Essential Medicines (NLEM) in Thailand; thus, a majority of Thai
patients need to pay for the cost of their prescription them-
selves. This has resulted in only a minority of osteoporosis pa-
tients currently receiving treatment.
This present study was conducted as a result of a request
from the Subcommittee for Development of the NLEM to pro-
vide information on the long-term effectiveness and cost-effec-
tiveness of the screening of osteoporosis and its medical man-
agement. This information was then used to inform the
Subcommittee regarding the selection of osteoporosis drugs for
public reimbursement nationwide [12]. It is expected that the
findings from this study will be useful to decision makers in
other developing countries, where health resources and infra-
structure are constraints and the screening and treatment of
osteoporosis are underutilized.
Methods
Analyses and model
Thehybridmodel consisting of a decision tree and aMarkovmodel
(Fig. 1) was constructed to compare the short- and long-term costs
and outcomes of systematic screening for osteoporosis among
postmenopausal women and offering medical management to
those diagnosed with osteoporosis. Quality-adjusted life-years
(QALYs)were used as an outcomemeasure in the analysis because
they contain both longevity and quality of life, allowing compari-
sons across different diseases and treatment modalities. The
study was conducted in regard to the Thai context by using the
societal viewpoint, with a hypothetical cohort of postmenopausal
women aged between 45 and 80 years. The lifetime time horizon
was used as the base case, with both costs and outcomes dis-
counted at 3%, as recommended by the guideline of economic
evaluation in Thailand [13]. All analyses were performed in Mi-
crosoft Excel® 2003 (Microsoft).
To identify the number of people who are diagnosed with os-
teoporosis, a decision tree was then developed by comparing the
costs and consequences of three screening strategies, namely, 1)
“null” scenario, 2) a systematic screening using DXA, and 3) a sys-
Fig. 1 – Decision tree illustrating two systematic screening c
representing a disease partway once postmenopausal womtematic screening using OST and sequential DXA. For the null sce-nario, no screening and no treatment was offered besides calcium
and vitamin D supplements. Only those who were confirmed
with DXA to have low BMD received medical management. The
Markov model was, then, used to compare the long-term cost
and outcome of treating osteoporosis based on the nature of the
disease’s progression (presented as “M” signs at the end of the
decision tree). All hypothetic cohorts of those who had been
diagnosed with osteoporosis received either calcium and vita-
min D supplements, null, or four choices of treatment: alendro-
nate, risedronate, raloxifine, or nasal calcitonin for both the
primary prevention—prevention of fragility fractures in women
with osteoporosis—and the secondary prevention—prevention of
new fractures in women with osteoporosis and a previous history
of fragility fractures. All the four drugs are widely available and
commonly used under the Thai health-care setting for averting
osteoporosis-related fractures [11]. The comparatorswere also ap-
proved as appropriate alternatives for the treatment of osteoporo-
sis in Thailand by Thai experts (a senior orthopedist, endocrinol-
ogists, and a gynecologist) (see details in the “Acknowledgment”
section). Consequences only fromhip and vertebral fractureswere
considered in the Markov model because a number of studies had
indicated a nonsignificant difference in mortality and morbidity
among patients with wrist fractures and among the general pop-
ulation [5–7]. This model was then validated by the same group of
experts. The model worksheet is freely available online at
www.hitap.net/projects_detail_en.php?p_id90.
Model inputs
Key parameters used in the decision models are summarized in
Table 1. Because the aim of this analysis was to inform decision
makers in Thailand, we identified the parameters from sources
that were most relevant to the Thai context [3,11,16,19], and if not
applicable, international publications [7,14,15,17,18,20] were re-
trieved. The effectiveness, in terms of relative risk reduction of
vertebral and hip fractures, of each drug was derived from litera-
ture searches and meta-analysis by using a Bayesian mixed treat-
ment comparison. The justification of each parameter and details
of systematic review and meta-analysis are available in the Sup-
plemental Materials found at doi:10.1016/j.jval.2011.11.015. For in-
tercountry comparisons, costs can be converted into US dollars by
using the purchase power parity exchange rate of US$1  12.615
THB (Thai baht) [21]. All costs were adjusted to 2007 values by
are to ‘Null’ scenario, followed by Markov model
e diagnosed with osteoporosis.omp
en arusing the general consumer price index [22].
S22 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 2 0 – S 2 8Table 1 – Model parameters, value, parameter distribution, and data sources used in the Markov model and the decision
tree model.
Parameters Mean (SE) Parameter
distribution
Data source
1. Epidemiological data
Prevalence of osteoporosis
In women aged between 40 and 44 y 0.0040 (0.0040) Gamma [3]
In women aged between 45 and 49 y 0.0160 (0.0160) Gamma [3]
In women aged between 50 and 54 y 0.0490 (0.0490) Gamma [3]
In women aged between 55 and 59 y 0.1030 (0.1030) Gamma [3]
In women aged between 60 and 64 y 0.2010 (0.2010) Gamma [3]
In women aged between 65 and 69 0.3260 (0.3260) Gamma [3]
In women aged between 70 and 74 y 0.4960 (0.4960) Gamma [3]
In women aged 75 years and above 0.5920 (0.5920) Gamma [3]
Transitional probability of the following vertebral and hip fractures
Osteoporosis patient with previous vertebral fracture developing the second
vertebral fracture in the following year
0.0290 (0.0057) Beta [14]
Osteoporosis patient with previous hip fracture developing the second hip
fracture in the following year
0.0136 (0.0051) Beta [14]
Osteoporosis patient with current vertebral fracture developing hip fracture
in the following year
0.0124 (0.0037) Beta [14]
Osteoporosis patient with current hip fracture developing vertebral fracture
in the following year
0.0362 (0.0081) Beta [14]
Osteoporosis patient with previous vertebral fracture developing hip fracture
in the following year
0.0068 (0.0028) Beta [14]
Osteoporosis patient with previous hip fracture developing vertebral fracture
in the following year
0.0178 (0.0059) Beta [14]
Osteoporosis patient with current vertebral fracture developing second
vertebral fracture in the following year
0.0293 (0.0057) Beta [14]
Osteoporosis patient with current hip fracture developing second hip
fracture in the following year
0.0190 (0.0060) Beta [14]
2. Accuracy of screenings and effectiveness of treatments
Accuracy of screenings
Sensitivity of OST to detect osteoporosis 0.9100 (0.0740) Gamma [15]
Specificity of OST to detect osteoporosis 0.5700 (0.1122) Gamma [15]
Effectiveness of treatments
Alendronate RR reduction in vertebral fracture 0.5660 (0.0906) Gamma Meta-analysis
Alendronate RR reduction in second vertebral fracture 0.5024 (0.0716) Gamma
Alendronate RR reduction in hip fracture 0.5824 (0.1286) Gamma
Risedronate RR reduction in vertebral fracture 0.6473 (0.2630) Gamma
Risedronate RR reduction in second vertebral fracture 0.5450 (0.0642) Gamma
Risedronate RR reduction in hip fracture 0.6533 (0.1097) Gamma
Raloxifene RR reduction in vertebral fracture 0.5009 (0.0799) Gamma
Raloxifene RR reduction in second vertebral fracture 0.5870 (0.0666) Gamma
Raloxifene RR reduction in hip fracture 1.0063 (0.2368) Gamma
Nasal calcitonin RR reduction in vertebral fracture 0.6079 (0.2169) Gamma
Nasal calcitonin RR reduction in second vertebral fracture 0.7358 (0.1230) Gamma
Nasal calcitonin RR reduction in hip fracture 0.4648 (0.2373) Gamma
3. Costs and the resource used
Annual cost of alendronate 10 mg 16,255.56 *
Annual cost of risedronate 5 mg 14,707.68 *
Annual cost of raloxifene 60 mg 19,221.00 [16]
Annual cost of nasal calcitonin 200 IU 60,000.00 *
Cost per visit to outpatient department for osteoporosis patient (exclude drugs) 497.88 (26.76) Gamma [11]
Average number of outpatient visits per year for osteoporosis patient 4.26 (0.50) Gamma [11]
Cost per visit to outpatient department for osteoporosis patient with vertebral
fracture (exclude drugs)
1921.34 (688.72) Gamma [11]
Average number of outpatient visits per year for osteoporosis patient with
vertebral fracture
10.41 (1.47) Gamma [11]
Cost per visit to inpatient department for osteoporosis patient with vertebral
fracture (excluding drugs)
56,588.56 (20,007.08) Gamma [11]
Average number of inpatient visits per year for osteoporosis patient with
vertebral fracture
1.00 (0.50) Gamma [11](continued on next page)
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Two types of sensitivity analysis concerning both parameter un-
certainty and assumptions used in the model were examined. For
the first source of uncertainty, a probabilistic sensitivity analysis
was carried out by using 1000 times the second-order Monte Carlo
simulation that incorporates the statistical uncertainty, that is,
probability distributions for the input variables, into the model
(see Table 1 for the distribution used). The rationale for the selec-
tion of distributional assumption for each variable has been illus-
trated in detail elsewhere [23]. Cost-effectiveness acceptability
curves were provided to show the relationship between the values
of the ceiling ratio (willingness to pay for a QALY gained [WTP/
QALY]) and the probability of favoring each treatment strategy. To
quantify the ceiling ratio for the Thai population, we applied the
threshold that was recommended by the Subcommittee for Devel-
opment of the NLEM, in which results from this study were fed to
the Subcommittee to decide whether or not to include these drugs
in the NLEM. This threshold was set at 100,000 THB [24] where the
current gross domestic product (GDP) per capita in the year 2005
was 120,036 THB [25].
For the second source of uncertainty, methodological uncer-
tainty [26], the impact of different assumptions used in themodel,
which are drug compliance and treatment duration, was exam-
ined. It was recognized that the treatment of osteoporosis was
associated with low drug compliance, especially among those
with longer treatment times [27]. Because our reference case as-
sumes 100% compliancewith therapy, it is worthwhile to examine
the effect of different drug compliance by using information from
existing published literature [27]. The probabilities of patients con-
Table 1 (continued)
Parameters
Cost per visit to outpatient department for osteoporosis patient with
fracture (exclude drugs)
Average number of outpatient visits per year for osteoporosis patien
fracture
Cost per visit to inpatient department for osteoporosis patient with h
fracture (exclude drugs)
Average number of inpatient visits per year for osteoporosis patient
fracture
Cost per visit to outpatient department for osteoporosis patient follo
vertebral fracture (exclude drugs)
Average number of outpatient visits per year for osteoporosis patien
previous vertebral fracture
Cost per visit to outpatient department for osteoporosis patient follo
fracture (exclude drugs)
Average number of outpatient visits per year for osteoporosis patien
previous hip fracture
Nonmedical direct cost of osteoporosis patient
Nonmedical direct cost of osteoporosis patient with fracture
Cost of OST screening
Cost of DXA screening
Traveling cost per visit
Food cost per visit
4. Utility estimates
Utility of osteoporosis patients
Utility of vertebral fracture patients
Utility of post–vertebral fracture patients
Utility of hip fracture patients
Utility of post–hip fracture patients
DXA, dual-energy X-ray absorptiometry; IU, international units; OST
* The quoted price submitted by pharmaceutical companies to the S
(October 2007).tinuing to use bisphosphonates, raloxifene, or calcitonin in thefirst 3 years following the initial treatment are given in Table 2. No
further discontinuation of the drugs after the third year of treat-
ment was assumed.
In addition, empirical evidence showed that after continuous
bisphosphonate treatment for some periods of time, for example,
5 years, the protective effect in terms of the prevention of osteo-
porotic fractures is still sustained for up to 5 years after discontin-
uation of the drugs [28–30]. We assumed in our model that this
assumption holds for both alendronate and risedronate but not for
other groups of osteoporotic drugs. Currently, there are no pub-
lished results of the effect of discontinuation beyond 10 years, and
so our sensitivity analysis applied a 10-year time horizon from the
time of initial treatment.
Mean (SE) Parameter
distribution
Data source
354.5 (47.99) Gamma [11]
hip 7.14 (0.66) Gamma [11]
77,537.04 (11,191.51) Gamma [11]
hip 1.00 (0.27) Gamma [11]
497.88 (26.76) Gamma [11]
4.89 (0.82) Gamma [11]
hip 497.88 (26.76) Gamma [11]
4.89 (0.82) Gamma [11]
7,635.56 (3,453.85) Gamma Survey
38,250.33 (15,375.99) Gamma Survey
497.88 (26.76) Gamma [11]
786.85 (182.22) Gamma [11]
525.56 (191.15) Gamma Survey
78.89 (19.40) Gamma Survey
0.9100 (0.0153) Beta [17]
0.7200 (0.0293) Beta [18]
0.9310 (0.0077) Beta [18]
0.7970 (0.0140) Beta [18]
0.8990 (0.0064) Beta [18]
oporosis Self-Assessment Tool; RR, relative risk; SE, standard error.
mittee for Development of the National List of Essential Medicines
Table 2 – Probabilities of patients continue using
bisphosphonates, raloxifene, or nasal calcitonin in the
following years for the first 3 years.
Year in
which
drugs
are taken
Probabilities of discontinuation
Bisphosphonates Raloxifene Nasal
calcitonin
Year 1 0.3500 (0.0321) 0.5800 (0.0201) 0.5000 (0.0195)
Year 2 0.2200 (0.0598) 0.4100 (0.0353) 0.3200 (0.0411)
Year 3 0.1400 (0.1157) 0.3200 (0.0566) 0.1900 (0.0951)hip
t with
ip
with
wing
t with
wing
t with
, Oste
ubcomValues indicate mean and standard error.
6S24 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 2 0 – S 2 8Results
Treatment options for the prevention of osteoporotic
fractures
Tables 3 and 4 shows lifetime costs and QALYs, respectively, of
providing each treatment to osteoporosis patients by age group
compared with a null scenario using the societal perspective. The
lifetime cost of treatments and QALYs for the prevention of osteo-
porotic fractures varies depending on the patient’s age at the start
of treatment and whether the patient had previous fractures and
drug regimens. It is obvious that treating patients at younger ages,
especially primary prevention, reflects a higher lifetime cost than
treating patients at older ages because our base-case analysis ap-
Table 3 – Lifetime costs of providing different medical man
group.
Age
(y)
Null
scenario
Alendronate Risedro
Primary
prevention
Secondary
prevention
Primary
prevention
45 234,066 550,571 248,634 519,782
50 220,097 508,469 234,437 480,273
55 200,590 458,379 214,633 433,022
60 181,365 410,201 193,858 387,566
65 159,325 356,732 170,546 337,151
70 140,387 307,298 150,558 290,798
75 120,888 259,651 130,468 246,344
80 104,115 219,738 112,212 208,924
Note: Costs are given in 2007 Thai baht.
Table 4 – Quality-adjusted life-years of providing different
patients by age group.
Age
(y)
Null
scenario
Alendronate Risedro
Primary
prevention
Secondary
prevention
Primary
prevention
45 17.869 18.413 17.878 18.300
50 16.219 16.800 16.227 16.703
55 14.473 15.080 14.481 14.991
60 12.784 13.372 12.792 13.267
65 11.042 11.599 11.049 11.500
70 9.392 9.869 9.398 9.786
75 7.984 8.332 7.990 8.264
80 6.730 6.975 6.734 6.930
Fig. 2 – Incremental cost-effectiveness plane illustrating
two selected age group, 50 years and 80 years.plied lifetime treatment costs. The total lifetime costs of disease
management increased with the addition of osteoporosis drugs.
Comparing between different treatments of osteoporosis, risedro-
nate had the lowest cost followed by alendronate, raloxifene, and
nasal calcitonin. Nasal calcitonin, however, yielded the highest
QALYs gained in the primary prevention of osteoporosis, followed
by alendronate, risedronate, and raloxifene. It is noteworthy that
providing secondary prevention added very little QALYs gained
compared with the null scenario.
Compared with the null scenario, alendronate provided the
lowest incremental cost-effectiveness ratio (ICER) for both pri-
mary and secondary prevention followed by risedronate, ralox-
ifene, and nasal calcitonin.When providing treatment for patients
ents to postmenopausal osteoporosis patients by age
Raloxifene Nasal calcitonin
ndary
ention
Primary
prevention
Secondary
prevention
Primary
prevention
Secondary
prevention
,263 611,129 251,836 1,437,414 290,558
,076 563,602 237,594 1,317,788 275,747
,298 507,954 217,701 1,186,401 254,920
,676 453,886 196,595 1,056,769 229,778
,480 394,702 173,003 917,941 202,799
,593 339,958 152,767 785,369 179,783
,558 288,271 132,565 662,275 158,205
,442 244,479 113,974 557,321 135,574
ical managements to postmenopausal osteoporosis
Raloxifene Nasal calcitonin
ndary
ention
Primary
prevention
Secondary
prevention
Primary
prevention
Secondary
prevention
.877 18.231 17.875 18.452 17.875
.226 16.598 16.224 16.831 16.224
.480 14.873 14.478 15.136 14.478
.791 13.154 12.789 13.425 12.789
.048 11.392 11.047 11.662 11.047
.398 9.658 9.396 9.932 9.397
.989 8.163 7.988 8.367 7.989
.734 6.849 6.732 7.015 6.733
Fig. 3 – Incremental cost-effectiveness ratios of providing
different universal screening strategies at various ageagem
nate
Seco
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111med
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9
7groups.
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S25V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 2 0 – S 2 8without prior fractures, primary prevention was more cost-effec-
tive than secondary prevention. Primary and secondary preven-
tion of osteoporotic fractures for older women (up to 75 years old)
was found to be more cost-effective. Figure 2 demonstrates the
esults of the base-case ICERs for the primary prevention of osteo-
orotic fractures comparedwith the null scenario in patients aged
0 and 80 years. Providing primary prevention with alendronate
ielded 496,286 THB per QALY for patients aged 50 years and
71,811 THB per QALY for patients aged 80 years. Alendronate
ffered 1,753,378 THB per QALY for a patient aged 50 years and
,702,343 THB per QALY for a patient aged 80 years in the second-
ry prevention.
Adding screening to diagnose osteoporosis
Because offering alendronate for the primary prevention of osteo-
porotic fractures gave the best value for money, it was used to
estimate the ICERs of adding systematic screening (Fig. 3). OST and
Fig. 4 – Cost-effectiveness acceptability curves of treatment
prevention of osteoporotic fractures at the ages of 50 and 80
prevention of osteoporotic fractures at the ages of 50 and 80.sequential DXA was a favorable option for universal screening
among the younger age groups (45–55 years). There was, however,
only a slight difference in ICERs between OST and sequential DXA,
and DXA alone among older age groups (60–80 years). The ICER of
screeningwithOST and sequential DXAwas lowest at 351,459 THB
(for patients 65 years old) and highest at 753,229 THB (for patients
45 years old).
Sensitivity analysis
Figure 4 presents cost-effectiveness acceptability curves and sum-
marizes the robustness of the model regarding uncertainty about
the costs and effects of each treatment strategy in both primary
(Fig. 4A) and secondary prevention (Fig. 4B). The findings present
the different results of themodel for patients aged 50 and 80 years.
If decision makers are willing to pay less than 100,000 THB per
QALY, the null scenario is the best policy option for both primary
and secondary prevention of osteoporotic fractures in osteoporo-
ns (A) in patients who start the treatments for primary
n patients who start the treatments for secondaryoptio
(B) i
S26 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 2 0 – S 2 8sis patients aged 50 and 80 years; however, if decision makers are
willing to pay beyond this threshold, that is, 600,000 THB per QALY
for primary prevention and 1,700,000 THB per QALY for secondary
prevention, treatment with alendronate and risedronate becomes
the better option. In addition, the patient’s age did not strongly
affect the results shown in the cost-effectiveness acceptability
curves.
In comparison to the null scenario, offering systematic
screening by using DXA among postmenopausal women and
treatment with alendronate, if appropriate, become a better
choice when the WTP threshold reaches 650,000 THB per QALY
and 750,000 THB per QALY at the age of 80 and 50 years, respec-
tively (see Fig. 5).
Results of the sensitivity analysis concerning methodological
uncertainties, that is, drug compliance and discontinuation of bi-
sphosphonates, are depicted in Figures 6 and 7 for the primary and
secondary prevention of osteoporotic fractures, respectively. Ad-
justing for only drug compliance provides little difference in terms
of ICERs across themedications for the prevention of osteoporotic
Fig. 5 – Cost-effectiveness acceptability curves of screening m
and 80. If positive results confirm with DXA, alendronate wi
osteoporotic fractures.
Fig. 6 – One-way sensitivity analysis of adjusting drug
compliance of all drugs and discontinuation of
bisphosphonate (Primary prevention of osteoporotic
fractures).fractures compared with the base cases (approximately 0.6–0.9
times). This is because the cost of treatmentwill be deducted if the
medication is stopped, which will limit the benefit of the drugs,
thereby causing minimal impact on the ICER. In the primary pre-
vention of osteoporotic fractures, the discontinuation of alendro-
nate and risedronate after 5 years of continuous treatment gener-
ates 49% higher ICERs compared with the base case because this
scenario is concerned with only 10-year treatment effect
whereby the increased chance of fractures was observed in the
older age groups. On the other hand, the discontinuation of
bisphosphonates in the secondary prevention halves their IC-
ERs compared with the base case because it significantly re-
duces the cost of treatment while the forgone benefit of pre-
venting fracture is minimized.
Discussion
This article aims to assess the value for money of providing com-
prehensive care, that is, screening and medical management, for
lities for osteoporosis in postmenopausal women ages 50
given to osteoporosis patients for primary prevention of
Fig. 7 – One-way sensitivity analysis of adjusting drug
compliance of all drugs and discontinuation of
bisphosphonate (Secondary prevention of osteoporoticoda
ll befractures).
S27V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 2 0 – S 2 8postmenopausal osteoporosis patients. It indicates that most of
the drugs offered additional QALYs compared with the null sce-
nario for both the primary and secondary prevention of osteopo-
rotic fractures among postmenopausal women. When comparing
the costs and outcomes of each drug, alendronate seemed to be
superior to other alternatives, followed by risedronate, raloxifene,
and nasal calcitonin. Providing treatment for the primary preven-
tion of osteoporotic fractures was found to be favorable to the
secondary prevention for all drugs because it offsets the cost of
treatment of the first fracture and also averts QALYs that would
have been lost from the worsening health states. In addition, the
ICERswere highest among very young and very old age groups and
lowest at the age of 70 years. This can be explained by the fact that
osteoporosis treatment is lifelong, and so providing treatment for
younger age groups than for older age groups is more expensive.
The lower fracture incidence rate, however, was observed among
patients with very old age groups (75 years or above). Results from
one-way sensitivity analyses indicated that adjusting for the drug
compliance of all drugs and discontinuation of bisphosphonates
did not change the conclusions in which the treatment is cost-
ineffective according to the Thai threshold.
Because the cost of the systematic screenings was minor
(0.54% for DXA, 0.31% for DXA sequential OST) compared with the
lifetime treatment cost for osteoporosis patients, adding either
of the systematic screenings into the economic model did not af-
fect the overall ICERs comparedwith the treatment alone. It seems
that using OST in conjunction with sequential DXA is superior to
the use of DXA alone, especially for the younger age groups. Be-
cause of the lower prevalence of osteoporosis in younger women,
providing amore expensive andmore accurate screening—DXA—
yielded higher ICERs.
Results from this study clearly demonstrated that the
screening and treatment of osteoporosis were not cost-effective
and that the drugs should not be included in the NLEM. The
threshold set was used in the NLEM 2008 revision. In the near
future, this threshold might be changed according to the na-
tion’s economic situation and the availability of information
from a research project that aims to identify the societal WTP
per QALY under the Thai setting [31].
To our knowledge, this was the first study that comprehen-
sively assessed the cost-effectiveness of screening and treatment
options for osteoporosis in postmenopausal women in a develop-
ing country. All previous economic evaluation studies were con-
ducted in Europe and North America where the cost of treatment
of fractures and theWTP per QALY are significantly higher than in
Thailand. However, this study is still comparable to those studies.
For example, a study conducted in Sweden revealed that providing
treatment with alendronate for osteoporosis in older women was
more cost-effective than treating younger women [32]. Another
study conducted in the United States concluded that alendronate
was the most favorable choice compared with hormonal replace-
ment therapy and raloxifene [33]. Our study, however, differs from
the Swedish study result, which favored secondary prevention
over primary prevention of osteoporotic fractures. This may be
because the Swedish study did not take into account the cost of
treating initial fractures in the model for secondary prevention.
We, however, considered that the cost should be included because
the government or society needs to pay for that treatment as well,
and so omitting this cost would lead to bias toward secondary
prevention.
There are some limitations regarding the design and data used
in this simulation study. First, this study was model based in
which input parameters were to be derived from various sources.
This would lead to a compromise in internal validity; instead,
most of the data were obtained from systematic reviews and
meta-analyses, which would increase the external validity or gen-
eralizability of the data. Second, the model focused on effective-ness of drugs in terms of prevention of hip and vertebral fractures
only and ignored the benefits of prevention of other fractures such
as wrist fractures. It also ignored other potential benefits of some
osteoporosis drugs, for example, a reduction in breast cancer in-
cidence by raloxifene [34]. Third, a utility score of 1 for the general
population was assumed. This would lead us to overestimate the
benefit of primary prevention compared with secondary preven-
tion. Fourth, it is true that assuming 100% accuracy of DXA may
overestimate aDXA-based strategy, especially universal screening
of DXA. Our findings, however, found in contrast that OST fol-
lowed by DXA is more cost-effective than universal DXA screen-
ing. Furthermore, it must be stated that the present study was
undertaken in the Thai setting and that the conclusions are not
necessarily applicable elsewhere, because costsmight be different
in other countries. In other settings, it would be necessary to ac-
quire country-specific data on the cost-effectiveness and inter-
vention thresholds.
Conclusions
At the current prices, it was concluded that screening andmedical
management to prevent osteoporotic fractures are cost-ineffec-
tive given the agreeable threshold set by the Subcommittee for
Development of the NLEM. The interventions have not yet been
included in the public health benefit packages, causing a signifi-
cant barrier for Thai women seeking access to appropriate screen-
ing and medical management of osteoporosis.
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